John McKearn, Arch Oncology chairman

Scoop: Roche-backed start­up gives up on CD47, lays off all em­ploy­ees

Arch On­col­o­gy end­ed its work on de­vel­op­ing an an­ti-CD47 an­ti­body and most em­ploy­ees have left the com­pa­ny, End­points News has learned.

The Bris­bane, CA, and St. Louis biotech scrapped clin­i­cal de­vel­op­ment of the an­ti­body, dubbed AO-176, ac­cord­ing to an au­to­mat­ic re­ply email from a for­mer clin­i­cal op­er­a­tions di­rec­tor.

All Arch em­ploy­ees were let go and the com­pa­ny “was in a wind-down sit­u­a­tion,” ac­cord­ing to the LinkedIn bio of Arch’s for­mer VP of hu­man re­sources.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.